Bill

Bill > HB1116


CO HB1116

CO HB1116
Plant-based Medicines


summary

Introduced
01/21/2022
In Committee
01/21/2022
Crossed Over
Passed
Dead
04/05/2022

Introduced Session

2022 Regular Session

Bill Summary

The bill creates the plant-based medicine policy review panel (policy review panel). The purpose of the policy review panel is to study the use of plant-based medicines to support mental health. The policy review panel operates for one year. The policy review panel shall submit a report on its findings and policy recommendations to the house of representatives public and behavioral health and human services committee and the senate health and human services committee, or any successor committees; the governor; and the department of human services. The bill defines "plant-based medicine" as a naturally occurring hallucinogenic plant-based compound. Forms of plant-based medicine only include psilocybin, psilocyn, dimethyltryptamine, and ibogaine.

AI Summary

This bill creates the plant-based medicine policy review panel (policy review panel) to study the use of plant-based medicines, such as psilocybin, psilocyn, dimethyltryptamine (DMT), and ibogaine, to support mental health. The policy review panel, which consists of 17 members appointed by the governor and legislative leaders, will analyze and make recommendations on the reclassification of these substances, decriminalization, safe production and distribution, testing, dosing, and oversight and regulation for their medical use. The panel will submit a report of its findings and policy recommendations to the legislature, the governor, and the state Department of Human Services by January 1, 2024, and the bill is repealed effective July 1, 2025.

Committee Categories

Health and Social Services

Sponsors (3)

Last Action

House Committee on Public & Behavioral Health & Human Services Postpone Indefinitely (on 04/05/2022)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...